vs
Side-by-side financial comparison of AC Immune SA (ACIU) and TAKEDA PHARMACEUTICAL CO LTD (TAK). Click either name above to swap in a different company.
TAKEDA PHARMACEUTICAL CO LTD is the larger business by last-quarter revenue ($4.3M vs $1.4M, roughly 3.0× AC Immune SA). TAKEDA PHARMACEUTICAL CO LTD runs the higher net margin — 3.4% vs -1622.4%, a 1625.8% gap on every dollar of revenue.
AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived th...
ACIU vs TAK — Head-to-Head
Income Statement — Q2 2025 vs Q1 2025
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $4.3M |
| Net Profit | $-23.3M | $144.2K |
| Gross Margin | — | 66.5% |
| Operating Margin | -1484.5% | 5.0% |
| Net Margin | -1622.4% | 3.4% |
| Revenue YoY | 90.1% | — |
| Net Profit YoY | 6.9% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $1.4M | $4.3M | ||
| Q2 24 | $755.7K | — | ||
| Q1 24 | — | $4.0M | ||
| Q3 22 | $4.3M | — |
| Q2 25 | $-23.3M | $144.2K | ||
| Q2 24 | $-25.0M | — | ||
| Q1 24 | — | $317.0K | ||
| Q3 22 | $-14.9M | — |
| Q2 25 | — | 66.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 69.1% | ||
| Q3 22 | — | — |
| Q2 25 | -1484.5% | 5.0% | ||
| Q2 24 | -3051.1% | — | ||
| Q1 24 | — | 12.2% | ||
| Q3 22 | -342.2% | — |
| Q2 25 | -1622.4% | 3.4% | ||
| Q2 24 | -3313.0% | — | ||
| Q1 24 | — | 7.9% | ||
| Q3 22 | -343.6% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $28.3M | $2.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $82.2M | $45.1B |
| Total Assets | $209.2M | $92.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $28.3M | $2.5B | ||
| Q2 24 | $56.7M | — | ||
| Q1 24 | — | $3.0B | ||
| Q3 22 | $49.0M | — |
| Q2 25 | $82.2M | $45.1B | ||
| Q2 24 | $135.8M | — | ||
| Q1 24 | — | $47.3B | ||
| Q3 22 | $209.1M | — |
| Q2 25 | $209.2M | $92.6B | ||
| Q2 24 | $261.3M | — | ||
| Q1 24 | — | $98.2B | ||
| Q3 22 | $226.1M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
